FIELD: medicine.
SUBSTANCE: invention relates to prediction of risk of unfavourable cardiovascular events in patients with ischemic heart disease (IHD) with type 2 diabetes mellitus (DM 2 type) after stenting coronary arteries. Invention can be used in cardiology, angiology, cardiac surgery, rehabilitation. For said purpose, immediately before stent, method includes determining in serum levels of markers of inflammation - lipoprotein-associated phospholipase A2 (Lp-PLA2) by enzyme immunoassay. Upon identifying in IHD patients with type 2 diabetes who underwent coronary stenting, Lp-PLA2 983 ng/ml or more, predict risk of adverse cardiovascular events.
EFFECT: invention allows to allocate priority group of IHD patients with type 2 diabetes who underwent coronary stenting, for organisation of follow-up with effective targeted interventions aimed at prevention of adverse cardiovascular events and in said patients to prevent high premature mortality.
1 cl, 3 tbl, 2 dwg, 2 ex
